![](/img/cover-not-exists.png)
PD-010 * Erlotinib attenuates bevacizumab-mediated activation of EGFR-survival signaling in CRC models independent of KRAS status providing a rational basis for the DREAM phase III clinical trial
Mesange, P., Bouygues, A., Muller, D., Savina, A., Chibaudel, B., Tournigand, C., Andre, T., de Gramont, A., Larsen, A.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv234.09
Date:
June, 2015
File:
PDF, 34 KB
english, 2015